Merck：今後の日程

今後の日程：0 ・すべてのピン：5

今後の予定はまだありません。最新：Merck Q2 2026: US$16.6 Billion Sales, Hikes Revenue Outlook, Terns Charge Hits Profit（2026年8月4日）

検索でMerckのピンをすべて見る

最近

企業2026/10/04@EconDesk
Merck Q2 2026: US$16.6 Billion Sales, Hikes Revenue Outlook, Terns Charge Hits Profit
126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.
開始 2026/08/04確定日付の確度: 確定確定として発表情報源が日付をどれだけ確定的に述べているか：確定、予定、推定、延期、未確認。「確定」のピンをすべて表示確度 86%総合信頼度: 86%ピンの情報源と参照がその日付をどれだけ裏付けているか。出典を含む 3 件の資料がピンの開始・終了時刻をどれだけ強く裏付けているかの加重平均。最新の資料より180日古くなるごとに重みは半分になります確度75%以上のピンをすべて表示62 日前Merck's^[1][3] release is dated August 4, 2026 (6:30 am EDT) and CNBC's^[2] coverage is 'Published Tue, Aug 4 2026'.
On 4 August 2026 Merck reported second-quarter sales of US$16.6 billion, up 5 percent, with Keytruda at US$8.4 billion, and raised its 2026 sales outlook while a US$2.31 per share Terns charge caused a loss.
健康2026/10/04@HealthDesk
FDA Approves Merck's Lipfendra, the First Oral PCSK9 Inhibitor
126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.
開始 2026/07/16確定日付の確度: 確定確定として発表情報源が日付をどれだけ確定的に述べているか：確定、予定、推定、延期、未確認。「確定」のピンをすべて表示確度 83%総合信頼度: 83%ピンの情報源と参照がその日付をどれだけ裏付けているか。出典を含む 5 件の資料がピンの開始・終了時刻をどれだけ強く裏付けているかの加重平均。最新の資料より180日古くなるごとに重みは半分になります確度75%以上のピンをすべて表示81 日前Merck's^[1][2] news release is dated July 16, 2026 and says the FDA 'has approved LIPFENDRA (enlicitide) tablets 20 mg'; Practical Neurology^[4] and the Family Heart^[5] Foundation report the same.
On 16 July 2026 the FDA approved Merck's Lipfendra (enlicitide), a once-daily 20 mg tablet and the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia.
企業2026/10/04@EconDesk
Merck to Buy Terns for US$6.7 Billion for a Leukemia Drug
126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.
開始 2026/03/25確定日付の確度: 確定確定として発表情報源が日付をどれだけ確定的に述べているか：確定、予定、推定、延期、未確認。「確定」のピンをすべて表示確度 83%総合信頼度: 83%ピンの情報源と参照がその日付をどれだけ裏付けているか。出典を含む 4 件の資料がピンの開始・終了時刻をどれだけ強く裏付けているかの加重平均。最新の資料より180日古くなるごとに重みは半分になります確度75%以上のピンをすべて表示194 日前The Merck and Terns news release (SEC^[1] Exhibit 99.1) is datelined 'RAHWAY, N.J., and FOSTER CITY, Calif., March 25, 2026' and Pharmaceutical Technology reported it the same day.
On 25 March 2026 Merck agreed to acquire Terns Pharmaceuticals for US$53.00 per share in cash, about US$6.7 billion, to get TERN-701, an oral allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia.
$6.7B
企業2026/10/04@EconDesk
Merck Completes Cidara Takeover to Add a Long-Acting Flu Antiviral
126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.
開始 2026/01/07確定日付の確度: 確定確定として発表情報源が日付をどれだけ確定的に述べているか：確定、予定、推定、延期、未確認。「確定」のピンをすべて表示確度 87%総合信頼度: 87%ピンの情報源と参照がその日付をどれだけ裏付けているか。出典を含む 3 件の資料がピンの開始・終了時刻をどれだけ強く裏付けているかの加重平均。最新の資料より180日古くなるごとに重みは半分になります確度75%以上のピンをすべて表示271 日前Merck's^[1][3] release, dated January 7, 2026, says it 'today announced the successful completion of the cash tender offer' for Cidara, with the tender expiring 11:59 p.m. ET on January 6.
On 7 January 2026 Merck announced the completion of its cash tender offer for Cidara Therapeutics at US$221.50 per share, gaining CD388, a long-acting antiviral for preventing influenza.
健康2026/10/04@HealthDesk
FDA Approves Merck's Keytruda, the First Anti-PD-1 Cancer Drug in the US
126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.
開始 2014/09/04確定日付の確度: 確定確定として発表情報源が日付をどれだけ確定的に述べているか：確定、予定、推定、延期、未確認。「確定」のピンをすべて表示確度 83%総合信頼度: 83%ピンの情報源と参照がその日付をどれだけ裏付けているか。出典を含む 3 件の資料がピンの開始・終了時刻をどれだけ強く裏付けているかの加重平均。最新の資料より180日古くなるごとに重みは半分になります確度75%以上のピンをすべて表示12.1 年前Merck's^[1] release is dated September 4, 2014 and says the FDA 'has approved KEYTRUDA'; The Pharmaletter^[3] (5 September 2014) reports the agency announced it 'late yesterday'.
On 4 September 2014 the FDA granted accelerated approval to Merck's Keytruda (pembrolizumab) for advanced melanoma, the first anti-PD-1 therapy approved in the United States.

Merck Q2 2026: US$16.6 Billion Sales, Hikes Revenue Outlook, Terns Charge Hits Profit

126 East Lincoln Avenue, Rahway, New Jersey, United States

Merck & Co.

Merck Q2 2026: US$16.6 Billion Sales, Hikes Revenue Outlook, Terns Charge Hits Profit

開始 2026/08/04確定確度 86%62 日前Merck's^[1][3] release is dated August 4, 2026 (6:30 am EDT) and CNBC's^[2] coverage is 'Published Tue, Aug 4 2026'.

On 4 August 2026 Merck reported second-quarter sales of US$16.6 billion, up 5 percent, with Keytruda at US$8.4 billion, and raised its 2026 sales outlook while a US$2.31 per share Terns charge caused a loss.

健康2026/10/04@HealthDesk

FDA Approves Merck's Lipfendra, the First Oral PCSK9 Inhibitor

126 East Lincoln Avenue, Rahway, New Jersey, United States

Merck & Co.

FDA Approves Merck's Lipfendra, the First Oral PCSK9 Inhibitor

開始 2026/07/16確定確度 83%81 日前Merck's^[1][2] news release is dated July 16, 2026 and says the FDA 'has approved LIPFENDRA (enlicitide) tablets 20 mg'; Practical Neurology^[4] and the Family Heart^[5] Foundation report the same.

On 16 July 2026 the FDA approved Merck's Lipfendra (enlicitide), a once-daily 20 mg tablet and the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia.

企業2026/10/04@EconDesk

Merck to Buy Terns for US$6.7 Billion for a Leukemia Drug

126 East Lincoln Avenue, Rahway, New Jersey, United States

Merck & Co.

Merck to Buy Terns for US$6.7 Billion for a Leukemia Drug

開始 2026/03/25確定確度 83%194 日前The Merck and Terns news release (SEC^[1] Exhibit 99.1) is datelined 'RAHWAY, N.J., and FOSTER CITY, Calif., March 25, 2026' and Pharmaceutical Technology reported it the same day.

On 25 March 2026 Merck agreed to acquire Terns Pharmaceuticals for US$53.00 per share in cash, about US$6.7 billion, to get TERN-701, an oral allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia.

$6.7B

企業2026/10/04@EconDesk

Merck Completes Cidara Takeover to Add a Long-Acting Flu Antiviral

126 East Lincoln Avenue, Rahway, New Jersey, United States

Merck & Co.

開始 2026/01/07確定確度 87%271 日前Merck's^[1][3] release, dated January 7, 2026, says it 'today announced the successful completion of the cash tender offer' for Cidara, with the tender expiring 11:59 p.m. ET on January 6.

On 7 January 2026 Merck announced the completion of its cash tender offer for Cidara Therapeutics at US$221.50 per share, gaining CD388, a long-acting antiviral for preventing influenza.

健康2026/10/04@HealthDesk

FDA Approves Merck's Keytruda, the First Anti-PD-1 Cancer Drug in the US

126 East Lincoln Avenue, Rahway, New Jersey, United States

Merck & Co.

FDA Approves Merck's Keytruda, the First Anti-PD-1 Cancer Drug in the US

開始 2014/09/04確定確度 83%12.1 年前Merck's^[1] release is dated September 4, 2014 and says the FDA 'has approved KEYTRUDA'; The Pharmaletter^[3] (5 September 2014) reports the agency announced it 'late yesterday'.

On 4 September 2014 the FDA granted accelerated approval to Merck's Keytruda (pembrolizumab) for advanced melanoma, the first anti-PD-1 therapy approved in the United States.

Merck：今後の日程

最近

Merck Q2 2026: US$16.6 Billion Sales, Hikes Revenue Outlook, Terns Charge Hits Profit

FDA Approves Merck's Lipfendra, the First Oral PCSK9 Inhibitor

Merck to Buy Terns for US$6.7 Billion for a Leukemia Drug

Merck Completes Cidara Takeover to Add a Long-Acting Flu Antiviral

FDA Approves Merck's Keytruda, the First Anti-PD-1 Cancer Drug in the US

関連タグ

Merck：今後の日程

最近

Merck Q2 2026: US$16.6 Billion Sales, Hikes Revenue Outlook, Terns Charge Hits Profit

FDA Approves Merck's Lipfendra, the First Oral PCSK9 Inhibitor

Merck to Buy Terns for US$6.7 Billion for a Leukemia Drug

Merck Completes Cidara Takeover to Add a Long-Acting Flu Antiviral

FDA Approves Merck's Keytruda, the First Anti-PD-1 Cancer Drug in the US

関連タグ

企業